HEALTH OF WOMAN. 2019.10(146): 72–76; doi 10.15574/HW.2019.146.72
Kravchenko E. V.
HSSEU « Bukovinian state medical University», Chernivtsi

The objective: was to determine the effectiveness of the use of complex therapy in the treatment of diffuse forms of dishormonal breast dysplasia (DВD) in women of early reproductive age.
Materials and methods. Under observation were 42 women with a diffuse form of BPH at the age of 25–31 years. The control group consisted of 20 healthy non-pregnant women, parity in age, social status and living conditions. The diagnosis of DВD was established on the basis of the analysis of anamnestic data, patient complaints, clinical data, X-ray and ultrasound studies carried out on the 5–7 day of the menstrual cycle.
Results. In 35 (83.3%) patients, DВD developed against the background of a normal biphasic menstrual cycle, in 7 (16.7%) – with an inferior luteal phase. During an instrumental examination, 23 (54.8%) of the women were diagnosed with fibrocystic form of DВD, 15 (35.7%) had adenofibromatosis, and 4 (9.5%) had glandular cystic mastopathy.
The use of Enat 400, phytochemical oncoprotectors, venotonics and sedatives provides, in the vast majority (95.2%) of patients of early reproductive age, high clinical efficacy in the treatment of DВD. According to instrumental methods of breast imaging, the regression of DВD occurred in 38 (90.5%) of young patients.
Conclusions. In the treatment of DВD in patients of early reproductive age, Enat 400 in combination with other drugs, due to the antioxidant, antiproliferative, pro-apoptotic, antitumor activity of the therapy, have established themselves as effective and safe agents.
Key words: dyshormonal breast dysplasia, early reproductive age, pathogenesis, treatment, Enat 400.

REFERENCES

1. Azbukina LN. 2016. Dobrokachestvennyie zabolevaniya molochnyih zhelez u zhenschin reproduktivnogo vozrasta. Meditsinskiy almanah 5 (45): 101–104.

2. Kornatska AH, Dubenko OD. 2012. Fitoselektyvna terapiia u zhinok z bezplidnistiu ta dobroiakisnymy zakhvoriuvanniamy molochnykh zaloz na etapakh reabilitatsii reproduktyvnoi funktsii. Zdorove zhenshchiny 6 (72): 218–221.

3. Molochnyie zhelezy i ginekologicheskie bolezni. Pod. red. Radzinskogo VE. M: 304. 2010.

4. Pashchenko SM, Reznichenko HI, Voloshyn MA. 2011. Diahnostyka ta likuvannia khvorykh na dyshormonalni hiperplazii molochnoi zalozy. Zaporizhzhia, Prosvita:152.

5. Pyrohova VI, Shurpiak SO, Oshurkevych OO. 2018. Terapiia reproduktyvnykh porushen z pozytsii podolannia oksydatyvnoho stresu. Zdorove zhenshchynы 10 (136):26–29.

6. Reznichenko HI, Reznichenko NIu, Potebnia VIu. 2016. Likuvannia dyshormonalnykh dysplazii hrudnykh zaloz. Zdorove zhenshchinу 3 (109): 93–98.

7. Smolanka II. 2015. Lechenie fibroznokistoznoy bolezni – put profilaktiki raka molochnoy zhelezyi. Reproduktivnaya endokrinologiya 2 (22): 65–69.

8. Tatarchuk TF, Kalugina LV, Efimenko OA. 2012. Opyit lecheniya mastalgii u patsientok s disgormonalnyimi zabolevaniyami molochnoy zhelezyi. Reproduktivnaya endokrinologiya 3 (5): 63–69.

9. Poola Indira, Jessy A, Marshalleck Josephine J. 2008, February 15. Poola Indira Risk Assessment for Breast Cancer Development in Patients with Ductal Hyperplasias. Clinical Cancer Research 14: 1274. https://doi.org/10.1158/1078-0432.CCR-07-4053; PMid:18281563

10. Rohan Thomas E, Negassa A, Rowan T. 2008. Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial. JNCI Journal of the National Cancer Institute 100 (8): 563–571. https://doi.org/10.1093/jnci/djn075; PMid:18398105